Alpha Tau Medical Ltd. filings document the company's foreign-issuer current reports for Alpha DaRT clinical and regulatory updates. Recent Form 6-K reports furnish press releases and presentations covering studies in recurrent glioblastoma, recurrent cutaneous squamous cell carcinoma, pancreatic cancer, and head and neck cancer.
The filings describe trial enrollment, interim clinical data, safety observations, FDA device-related matters, conference presentations and company presentations furnished as exhibits. They also identify the company's Form 20-F reporting status and the treatment of furnished information under the Securities Exchange Act.
Alpha Tau Medical Ltd. files a Form 144 notice for the proposed sale of 20,000 ordinary shares acquired upon exercise of employee stock options on 07/06/2026, with cash payment upon exercise. The filing also lists recent sales by the holder between 06/23/2026 and 07/02/2026, including multiple transactions totaling several blocks of ordinary shares.
Alpha Tau Medical Ltd. Chief Financial Officer Raphi Levy executed an exercise-and-sell transaction in company Ordinary Shares. He exercised 17,873 shares at $2.98 per share and then sold 17,873 shares in an open-market sale at an average price of $13.0027 per share on July 2, 2026.
Following these transactions, Levy directly holds 90,180 Ordinary Shares. The pattern shows option exercise to acquire shares and a same-day sale of an equivalent number of shares, while maintaining a substantial remaining equity position.
Alpha Tau Medical Ltd. Chief Financial Officer Raphi Levy reported an exercise-and-sale transaction in Ordinary Shares. Levy sold 2,127 shares in an open-market transaction at an average price of $13.0189 per share and reported direct ownership of 90,180 shares immediately afterward. The filing also shows a corresponding M-code transaction for 2,127 shares at $2.98 per share classified as a derivative exercise or conversion, indicating these shares were acquired through an option exercise before being sold.
Levy Raphi submitted a Form 144 notice to sell 20,000 Ordinary Shares of Alpha Tau Medical Ltd. acquired upon exercise of employee stock options, scheduled 07/01/2026 with cash payment upon exercise. The filing lists prior dispositions in June 2026: 17,500 shares on 06/23/2026, 20,000 shares on 06/25/2026, and 20,000 shares on 06/30/2026, each shown with gross proceeds in local currency.
Alpha Tau Medical Ltd. Chief Financial Officer Levy Raphi sold 20,000 Ordinary Shares in an open-market transaction. The shares were sold at an average price of $12.0022 per share. After this sale, Raphi directly holds 90,180 Ordinary Shares of Alpha Tau Medical.
Alpha Tau Medical Ltd. reported insider sales under a Form 144: two dispositions of ordinary shares totaling 37,500 shares in June 2026. The filing also records 65,750 shares issued on 04/01/2023 upon RSU vesting.
Alpha Tau Medical Ltd. Chief Financial Officer Raphi Levy reported open-market sales of 20,000 Ordinary Shares on June 25, 2026. The shares were sold in two transactions at a price of about $11.0002 per share. These transactions reflect a net reduction in his directly held shares.
Alpha Tau Medical Ltd. Form 144 notice reports resale activity and prior RSU issuances. The filing lists a broker-dealer, Oppenheimer & Co. Inc., with 20,000 shares and $201,000 dated 06/25/2026. It also shows that Raphi Levy sold 17,500 ordinary shares on 06/23/2026 for $167,051. The record includes earlier shares issued upon vesting of RSUs: 21,722 shares on 07/06/2022 and 65,750 shares on 04/01/2023.
Alpha Tau Medical Ltd. reported the results of its Annual General Meeting of Shareholders held on June 23, 2026 in Jerusalem. Shareholders re-elected David Milch and Ruth Alon as Class II directors, with terms running until the annual meeting expected in 2029.
They also re-approved the company’s Compensation Policy for Executive Officers and Directors, confirmed CEO Uzi Sofer to continue serving as both Chief Executive Officer and Chairman of the Board, approved his compensation package, and extended the terms of certain options for directors and officers.
In addition, shareholders re-appointed Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global, as independent registered public accounting firm for the year ending December 31, 2026, with the board authorized to set audit fees.
Alpha Tau Medical Ltd. Chief Financial Officer Levy Raphi reported selling a total of 17,500 Ordinary Shares in open-market transactions. The Form 4 shows two sales on June 23, 2026, at prices of $10.0004 and $9.47 per share. These are non-derivative transactions in the company’s common equity.